These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma? Devoy MA; Fuller RW; Palmer JB Chest; 1995 Apr; 107(4):1116-24. PubMed ID: 7705125 [No Abstract] [Full Text] [Related]
4. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Noppen M; Vincken W Respiration; 2000; 67(1):112-3. PubMed ID: 10705276 [No Abstract] [Full Text] [Related]
5. Long-acting beta(2)-agonists in childhood asthma: Don't change a winning team (yet). Verberne AA; de Jongste JC Pediatr Pulmonol; 2000 Mar; 29(3):169-71. PubMed ID: 10686035 [No Abstract] [Full Text] [Related]
7. Safety of long-acting beta-agonists--an urgent need to clear the air. Martinez FD N Engl J Med; 2005 Dec; 353(25):2637-9. PubMed ID: 16371628 [No Abstract] [Full Text] [Related]
8. Is there a need for another inhalative beta(2)-agonist besides formoterol in patients with asthma? Matthys H Respiration; 2001; 68(4):432-7. PubMed ID: 11464097 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of beta(2)-agonists in children. Kabesch M J Allergy Clin Immunol; 2009 Dec; 124(6):1195-6. PubMed ID: 19910024 [No Abstract] [Full Text] [Related]
10. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Frois C; Wu EQ; Ray S; Colice GL Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019 [TBL] [Abstract][Full Text] [Related]
13. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. Lipworth BJ; Aziz I J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Nightingale JA; Rogers DF; Barnes PJ Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of users of inhaled long-acting beta 2-agonists in a southern European population. Castellsague J; Garcia-Rodríguez LA; Pérez-Gutthann S; Agostinis L; Cattaruzi C; Troncon MG Respir Med; 1999 Oct; 93(10):709-14. PubMed ID: 10581659 [TBL] [Abstract][Full Text] [Related]
17. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Appleton S; Smith B; Veale A; Bara A Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594 [TBL] [Abstract][Full Text] [Related]
18. New pharmacologic agents in the treatment of asthma. Blaiss MS Allergy Proc; 1993; 14(1):17-21. PubMed ID: 8096486 [TBL] [Abstract][Full Text] [Related]
19. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. van der Woude HJ; Winter TH; Aalbers R Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351 [TBL] [Abstract][Full Text] [Related]
20. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. van Noord JA; Smeets JJ; Raaijmakers JA; Bommer AM; Maesen FP Eur Respir J; 1996 Aug; 9(8):1684-8. PubMed ID: 8866595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]